Kfir Schreiber

Kfir Schreiber, Co-founder and CEO of Deepcure, specializes in AI-driven small molecule therapies for autoimmune diseases. He discusses how AI is revolutionizing drug discovery by exploring previously unreachable chemical spaces. The conversation delves into the shift from biologics to small molecules, emphasizing their advantages in treatment. Kfir also highlights Deepcure's innovative techniques in generating effective inhibitors, showcasing the potential to turn challenging targets into viable therapies while reducing toxicity and improving patient outcomes.